A new bilingual telehealth clinic, Sol y Vida Clinic (solyvidaclinic.com), launched nationwide today, aiming to close a significant gap in metabolic care for Latino communities as the GLP-1 medication boom continues to reshape obesity and diabetes treatment. The launch coincides with Hispanic Heritage Month, which begins September 15, and seeks to address both language barriers and prescribing disparities that have left Hispanic patients behind in accessing the newest class of weight-loss drugs.
A 2024 national cohort study found that Hispanic patients are 47% less likely than White patients to be prescribed the newest GLP-1 medications. Furthermore, the National Hispanic Medical Association estimates that only 2% of eligible Latino patients access anti-obesity medications. Language compounds the problem: according to HHS, 68% of Hispanics and Latinos speak a language other than English at home. Sol y Vida Clinic offers medical weight loss and metabolic care from licensed telehealth clinicians in both English and Spanish, available in all 50 states.
“We created Sol y Vida to provide another option — one where patients can communicate comfortably, understand their care and have meaningful conversations with licensed healthcare professionals in the language they prefer,” said founder Edgar Estrada. The clinic’s approach emphasizes accessibility and transparency, beginning with a free 20-minute first consultation with no commitment. Licensed clinicians determine whether treatment is medically appropriate and prescribe accordingly. Programs include compounded semaglutide, dispensed by licensed compounding pharmacies. However, compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. Individual results vary.
The launch comes amid heightened regulatory scrutiny of telehealth marketing for compounded GLP-1 medications. Since late 2025, the FDA has sent three waves of warning letters over such marketing. Sol y Vida Clinic takes a different stance: it is LegitScript-certified (verifiable at legitscript.com), publishes its program prices, and its press kit lists the claims it will not make. The clinic’s philosophy, “recetado, no comprado” (prescribed, not purchased), is outlined at solyvidaclinic.com/blog/por-que-recetado-no-comprado.
This development matters because it directly confronts a documented inequity in the rapidly expanding market for GLP-1 drugs, which have become a cornerstone of metabolic medicine. By providing culturally and linguistically competent care, Sol y Vida Clinic could help increase access for a population that has been significantly underserved. The clinic’s emphasis on compliance and transparency may also set a standard in a field where regulatory oversight is increasing. For readers, this signals a potential new resource for affordable, bilingual weight-loss care and highlights the ongoing challenges of ensuring equitable healthcare innovation.
